Berenberg Initiates Coverage On Krystal Biotech with Buy Rating, Announces Price Target of $154
Portfolio Pulse from Benzinga Newsdesk
Berenberg analyst Caroline Palomeque has initiated coverage on Krystal Biotech (NASDAQ:KRYS) with a Buy rating and a price target of $154.
September 07, 2023 | 9:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech has been initiated with a Buy rating by Berenberg, with a price target of $154.
The initiation of coverage by Berenberg with a Buy rating and a high price target indicates a positive outlook for Krystal Biotech. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100